< Back to latest news & events

Blogs

Update on the Precision Breeding Act 2023: details emerge of the new simplified regulatory pathway for gene edited plant and animal derived food and feed products

January 2025

The Genetic Technology (Precision Breeding) Act 2023 could come into force as early as spring 2025. It empowers the Food Standards Agency (FSA) to create a new simplified regulatory pathway for the marketing authorisation of precision bred plants and animals, and derived food and feed products. Here we review the latest policy developments which shed light on what this new regulatory pathway will look like for applicants.

As a brief recap, the Act applies to animals, plants and algae, which are considered “precision bred” if their genome is altered using modern biotechnology in a stable (heritable) way that could have occurred through traditional breeding. The FSA is granted powers under the Act to establish a simplified, proportionate, and science-based regulatory pathway for the marketing authorisation of Precision Bred Organisms and food and feed produced from Precision Bred Organisms in the UK.

The FSA is currently developing this new regulatory pathway, the so-called Precision Breeding Regulatory Framework. Their Delivery Plan and Policy Update (linked below) were both updated last month, providing us with the most recent details on the practicalities of this new regulatory pathway.

Under the new pathway, organisms will first need to be confirmed as having Precision Bred Organism status by the Department for Environment, Food & Rural Affairs (Defra). This process will confirm their equivalence to traditionally bred organisms, which are not subject to premarket approval. Defra’s decision may take up to about 3 months. Only then can an application for food or feed authorisation be submitted to the FSA.

The FSA will implement a two-tiered food or feed marketing authorisation process. Tier 1 applications will be granted marketing authorisation without the need for a bespoke risk assessment. Instead, they will follow a new “lighter-touch” audit and registration process which is “greatly simplified compared to other regulated products processes”. The FSA estimates that decisions on Tier 1 applications will take two months.

Tier 2 applications, by contrast, will require a bespoke risk assessment focusing on specific safety concerns in a process that is “closely aligned with existing regimes”. The estimated timeframe for Tier 2 application decisions is significantly longer, taking 12 to 24 months depending on complexity. This complexity will be assessed by the FSA based on the novelty and scientific and risk management complexity of the application.

Applicants will need to determine the applicable tier to their product through a triage process based on a set of food safety criteria concerning novelty, nutritional quality, allergenicity, toxicity and other safety concerns. Products that raise any safety concerns will require Tier 2 approval. These concerns will presumably inform the focus of the bespoke risk assessment involved in Tier 2 applications.

The FSA estimates to receive about 18 applications per year, divided equally between the two tiers.

In short, the FSA is setting up a simpler faster (2 month) Tier 1 application process for the food and feed marketing authorisation of Precision Bred Organisms, alongside a bespoke slower (1-2 year) Tier 2 application process to tackle specific safety concerns. Questions remain about the exact triage criteria that will decide the tier of an application, with detailed guidance for applicants expected to be released soon.

Follow our Agritech Thymes blog for further developments.

Further reading

https://www.food.gov.uk/board-papers/precision-breeding-delivery-plan

https://www.food.gov.uk/board-papers/policy-development-precision-breeding


This article was written by Trainee Patent Attorney Aron Ferenczi

Latest updates

HGF Ranked #1 in the UK for Trade Mark Portfolios in the 2025 Trade Mark Filing Trends Report by Clarivate.

HGF has achieved the #1 ranking for the UK for trade mark portfolios in the newly released 2025 Trade mark Filing Trends report by Clarivate, recognising the firm as a …

Read article

The EPO Board of Appeal comments on the scope of the morality exclusion from patentability

The recent decision, T1553/22 of the Board of Appeal required the Board to consider the scope of the exclusions from patentability under Article 53(a) EPC. The invention in this case …

Read article

The Enlarged Board of Appeal has today issued its decision in seminal case G1/24

G1/24, described as one of the most important cases in decades, relates to how claims of patents are to be interpreted by the Boards of Appeal and, by extension, all …

Read article

UPC’s Hamburg Local Division provides guidance on the extent to which a patent may be used as its own “lexicon”

Agfa NV v Gucci & Anors. [UPC_CFI_278/2023] – Hamburg Local Division of the UPC (Klepsch, Schilling, Sarlin) – 30 April 2025 While we await a decision on G1/24 from the …

Read article

MevoCem Nominated for the Earthshot Prize by CIPA

We’re delighted to share that our client, Material Evolution, has been nominated by the Chartered Institute of Patent Attorneys (CIPA) for the globally renowned Earthshot Prize, in recognition of their …

Read article

Agritech Thymes: Agritech 2030: Forecasting the Technologies Poised to Transform Farming

Whilst yet to recover to the levels of 2011-2021, where capital invested in agritech increased 20-fold, investor funding in agritech is starting to pick up, and 2025 is set to …

Read article

UPC delivers first judgment on Validity and Infringement of a Second Medical Use Claim

Sanofi Biotechnology SAS & Anor v Amgen, Inc., & Ors– Thomas, Thom, Kupecz and Dorland-Galliot – [UPC_CFI_505/2024] The Dusseldorf Local Division (LD) has delivered the UPC’s first Judgment on second …

Read article